BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7703927)

  • 1. Pharmacoeconomics of antifungal therapy.
    Cooke J
    Bone Marrow Transplant; 1994; 14 Suppl 5():S18-20. PubMed ID: 7703927
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal amphotericin B for fever and neutropenia.
    Winston DJ; Schiller GJ; Territo MC
    N Engl J Med; 1999 Oct; 341(15):1154-5. PubMed ID: 10515755
    [No Abstract]   [Full Text] [Related]  

  • 3. Liposomal amphotericin B for fever and neutropenia.
    Rakita R
    N Engl J Med; 1999 Oct; 341(15):1153-4; author reply 1154-5. PubMed ID: 10515754
    [No Abstract]   [Full Text] [Related]  

  • 4. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
    Schneemann M; Bachli EB
    Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B deoxycholate: time to retire our old standard?
    Gallagher JC
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):313-6. PubMed ID: 15954845
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effective use of liposomal amphotericin B.
    O'Connell B; Craig JI; Marcus RE; Ludlam H
    Clin Lab Haematol; 2002 Oct; 24(5):317-9. PubMed ID: 12358895
    [No Abstract]   [Full Text] [Related]  

  • 8. Amphotericin B: is a lipid-formulation gold standard feasible?
    Spellberg B; Witt MD; Beck CK
    Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of non-conventional amphotericin B at the San Carlos Clinical Hospital].
    Prieto Yerro C; Vargas Castrillón E; Laredo Velasco L; Pérez-Cecilia E; Ambit Avila MI; Picazo de la Garza JJ
    Rev Esp Salud Publica; 2000; 74(4):351-9. PubMed ID: 11031843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply: Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
    Huprikar S
    Liver Transpl; 2008 May; 14(5):709. PubMed ID: 18433053
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.
    Nomura K; Kawasugi K; Morimoto T
    Eur J Cancer Care (Engl); 2006 Mar; 15(1):44-50. PubMed ID: 16441676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
    Reed A; Herndon JB; Ersoz N; Fujikawa T; Schain D; Lipori P; Hemming A; Li Q; Shenkman E; Vogel B
    Liver Transpl; 2007 Dec; 13(12):1743-50. PubMed ID: 18044769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B for fever and neutropenia.
    Prentice HG; Kibbler CC
    N Engl J Med; 1999 Oct; 341(15):1152-3; author reply 1154-5. PubMed ID: 10515751
    [No Abstract]   [Full Text] [Related]  

  • 15. Amphotericin B lipid preparations: what are the differences?
    Adler-Moore JP; Proffitt RT
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do not abandon amphotericin B as an antifungal bladder irrigant.
    Wise GJ
    Clin Infect Dis; 2005 Oct; 41(7):1073-4; author reply 1074. PubMed ID: 16142684
    [No Abstract]   [Full Text] [Related]  

  • 17. A perspective on liposomal amphotericin B (AmBisome).
    Richardson M; de Pauw B
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():1-4. PubMed ID: 18430125
    [No Abstract]   [Full Text] [Related]  

  • 18. Empirical antifungal therapy for persistent fever in patients with neutropenia.
    Chandrasekar PH
    Clin Infect Dis; 2001 Jan; 32(2):320-1. PubMed ID: 11170928
    [No Abstract]   [Full Text] [Related]  

  • 19. Current and future therapy of invasive fungal infections.
    Andriole VT
    Curr Clin Top Infect Dis; 1998; 18():19-36. PubMed ID: 9779349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?
    Lewis RE; Wiederhold NP
    Clin Infect Dis; 2003 Sep; 37(6):871-2. PubMed ID: 12955666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.